Management Discussion and Analysis For the Year Ended December 31, 2024

This Management Discussion and Analysis ("MD&A") has been prepared by management as at June 19, 2025, and it presents an analysis of the consolidated financial position of Planet Based Foods Global Inc. (the "Company") for the year ended December 31, 2024 The following information should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2024 and 2023, including the notes contained therein. The consolidated financial statements are prepared in accordance with IFRS® Accounting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Unless otherwise indicated, all dollar amounts are in US dollars.

Forward Looking Statements

This MD&A may contain certain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and factors may include, but are not limited to: unavailability of financing, changes in government regulation, general economic conditions, general business conditions, limited time being devoted to business by directors, escalating professional fees, and escalating transaction costs. Readers are cautioned not to place undue reliance on forward-looking statements, which are effective only as of the date of this MD&A or as of the date otherwise specifically indicated herein.

Actual results may differ materially and adversely from those expressed in any forward-looking statements. The Company undertakes no obligation to revise or update any forward-looking statements for any reason.

Company History and Business Overview

Planet Based Foods Global Inc. (formerly "Digital Buyer Technologies Corp.") (the "Company" or "PBF Global"), was incorporated on February 18, 2017 under the Business Corporations Act (British Columbia).

In May 2017, the Company issued a total of 12,510 common shares at \$2.50 per share for gross proceeds of \$31,275.

In January 2018, the Company issued a total of 87,020 common shares at \$2.50 per share for gross proceeds of \$217,550.

In January 2018, the Company issued a total of 147,000 common shares at \$5.00 per share for gross proceeds of \$735,000.

In February 2018, the Company entered Share Exchange Agreement ("Agreement") with Cryptobuyer Technologies (Panama) Corp. ("Crytobuyer Panama") with respect to acquire all of the issued and outstanding securities of Crytobuyer Panama from the holders thereof (collectively, the "Vendors"). Pursuant to the terms of the Agreement, the Company issued 393,500 common shares at price of \$5.00 per share to the Vendors in proportion to their holdings of common shares of Cryptobuyer Panama and a total of 2,000,000 preferred shares at a price of \$0.50 per share to certain Vendors in proportion to their holdings of preferred shares of Cryptobuyer Panama.

In March 2018, the Company issued a total of 43,000 common shares at \$5.00 per share for gross proceeds of \$215,000.

On July 3, 2018, the Company entered Share Sale Agreement ("Sale Agreement") with an individual, Jorge Luis Farias Sanchez to cancel 270,000 common share and 2,000,000 preferred shares of the Company hold by Jorge Luis Farias Sanchez and Robert Dzisiak.

On January 15, 2021, the Company completed a ten to one share consolidation. All references to share and per share amounts in this MD&A have been retroactively restated to reflect the ten to one share consolidation.

On April 7, 2021, the Company completed a private placement for total gross proceeds of \$300,000. The private placement consists of 1,200,000 units at \$0.25 per unit. Each unit consists of one common share of the Company and one-half of share purchase warrant. Each warrant is exercisable into an additional common share of the Company for

Management Discussion and Analysis For the Year Ended December 31, 2024

a period of two years at a price of \$3.00 per warrant. A value of \$nil has been attributed to the warrants using the residual method. The Company incurred of \$8,828 legal fees in connection with the private placement.

On June 28, 2021, the Company incorporated a wholly owned subsidiary, DBT (USA) Corp. in California USA.

On July 22, 2021, the Company amended its articles in order to change its authorized capital from an unlimited number of common shares, without par value, to an unlimited number of subordinate voting shares, eliminated a class of unlimited number of preferred shares, without par value, and created a new class of unlimited number of Multiple Voting Shares, all without par value.

On August 31, 2021, the Company completed its acquisition of Planet Based Foods Inc. ("PBF") by way of a three-cornered acquisition and amalgamation among the Company, PBF and DBT ("Transaction"). As part of the Transaction, the Company issued in aggregate, 3,123,356 subordinate voting shares and 800,000 multiple voting shares to the PBF shareholders for exchange all of the outstanding shares of PBF.

After the completion of the Transaction, the Company changed its name to "Planet Based Foods Global Inc.". In connection with the Transaction, Planet Based Foods Inc. merged with DBT (USA) Corp. to form the Subsidiary of the Company.

The Transaction has been accounted for in accordance with IFRS 2, Share-based payments. The Transaction is considered to be a reverse takeover of the Company by the acquiree. Although the Transaction resulted in PBF legally becoming a subsidiary of the Company, the transaction has been accounted for as a reverse takeover of the Company in accordance with guidance provided in IFRS 2 Share Based Payments. As the Company did not qualify as a business according to the definition in IFRS 3, this reverse takeover transaction did not constitute a business combination.

PBF was incorporated October 9, 2018, under the laws of the State of California, United States. The Company's primary focus is development of vegan meat-analog based products, made primarily from hemp plant derived proteins. The Company utilizes copacker relationships to manufacture and package its products for the wholesale market, including sales to restaurants and to resellers of Consumer Packaged Goods ("CPG"). The Company's branding and trademarks include the acronym: H.E.M.P. "Honorable Ethical Moral Protein."

PBF traces its lineage to a now defunct entity called Hemp Food Company, LLC ("HFC"), and acquired the recipes and related intellectual property ("Recipes") of HFC, at fair value in 2018.

PBF offers a superior, cost-efficient vegan meat analog derived from hemp proteins. The products have been developed as a sustainable and healthy alternative to meat proteins. The initial concepts for the hemp products began development as early as 2012, where the founders saw an opportunity in the meat-replacement market. With Soy based product popularity on a decline and vegan products as a whole becoming more popular, the Company set out to find a superior source of plant-based proteins. The Company determined that hemp derived products and proteins were poised to become the next superfood alternative in the plant-based foods market. With higher-yielding health benefits and more cost-efficient production methods, the Company believes hemp analogs offer a healthier product with better margins than current competitors in this market space.

During the year ended December 31, 2019, PBF developed and refined three initial product SKUs, including morning sausage, taco crumble and burger patties. PBF utilizes copacker relationships to manufacture and package its products for the wholesale market, including sales to restaurants and to resellers of Consumer-Packaged Goods ("CPG"). During 2019, PBF established its first co-packer relationship with West Liberty Foods ("WLF"), near Chicago, Illinois. By the end of 2019, PBF determined that research and development ("R&D") test production coming out of WLF did not meet the Company's consistency and quality needs for its products. PBF decided to discontinue the relationship with WLF, and return, dispose or abandon certain production equipment installed at WLF premises.

In the first half of 2020, PBF began working with a new co-packer, Aveno Antigua ("Aveno"), of Denver, Colorado. Aveno is a certified organic, certified Kosher, non-GMO, gluten-free and scalable food processing and co-packing manufacturer with deep roots in the rapid-growth plant-based foods segment of the food products industry. Aveno

Management Discussion and Analysis For the Year Ended December 31, 2024

also has the technical abilities to assist in production techniques and new product development. At the same time, PBF began "version 2.0" refinements of existing recipes.

During early to mid-2020, PBF began discussion with several large market participants, including restaurant supplier and distributor US Foods, Inc., with sample products distribution of the Version 2.0 productions. In addition, PBF has had initial discussions and sample distributions with buyers various direct to consumer retailers, including Target and others, indicating interest. PBF also worked with launch partners such as Creative Partners Group, a retail solutions company to develop sell-through and strategy in the CPG space.

In connection with the Transaction, The Company conducted a non-brokered private placement (the "Major Financing") in an amount of \$6,316,071 (CAD\$8,113,130. The Major Financing has been conducted via issuing subscription receipts (the "Subscription Receipts") at a price of CAD \$1.50 (the "Major Financing Price"). Each Major Financing Unit will consist of one fifth (1/5) subordinate voting share and one tenth (1/10) transferable subordinate voting share purchase warrant (each a "Major Financing Warrant"). Each whole Major Financing Warrant will entitle the holder to purchase one fifth (1/5) additional subordinate voting share from the Company at an exercise price of CAD \$3.00 per share for a period of two (2) years from the date of issuance. On December 17, 2021, the Subscription Receipts has been fully converted.

In August 2023, the Company closed the first and second tranche of non-brokered private placement of 341 convertible debenture units (the "Units") at a price of CAD\$1,000 per Unit for gross aggregate proceeds of CAD\$341,000. Each Unit issued comprised of: (i) CAD\$1,000 principal amount of 10% unsecured convertible debentures ("Convertible Debentures") issued by the Company with a maturity date ("Maturity Date") of 18 months from the date of issuance; and (ii) 1,000 subordinate voting share purchase warrants (each, a "Warrant") of the Company. Each Convertible Debenture is convertible at the holder's option into fully-paid subordinate voting shares of the Company ("Shares") at any time prior to the Maturity Date at a conversion price of CAD\$0.50 per Share. Each Warrant is exercisable into one Share of the Company at an exercise price of CAD\$1.00 for a period of 24 months from the date of issuance.

During the year ended December 31, 2023, the Company completed a five to one share consolidation. All references to options, warrants, conversions, share and per share amounts in the consolidated financial statements and accompanying notes to the consolidated financial statements have been retroactively restated to reflect the five to one share consolidation.

On May 31, 2024, the Company completed a non-brokered private placement of subordinate voting shares at a price of C\$0.10 per Share for gross aggregate proceeds of \$729,860 (CAD \$1,000,000).

Subsequent to December 31, 2024, the Company closed its strategic reorganization pursuant to the terms of a Share Purchase Agreement with PBF and certain insiders of the Company (together, the "Purchasers"), where all outstanding shares of PBF were transferred to the Purchasers in exchange for the surrender of their securities in the Company, and PBF transferred to the Company its proprietary recipes, trademarks, and related intellectual property assets (the "IP") in return for the Company forgiving approximately \$5.5 million in intercompany debt and granting PBF an exclusive license for the use of the IP within the United States, in exchange for a royalty on revenues derived therefrom.

The Company's head office is located at Suite 2250 – 1055 West Hastings Street, Vancouver. The Subsidiary's head office is located at 2869 Historic Decatur Road, San Diego, California 92106.

Management Discussion and Analysis For the Year Ended December 31, 2024

Selected Annual Information

Years Ended December 31,

	2024	2023	2022
	\$	\$	\$
Total Revenues	217,931	227,268	229,001
Net Loss	(1,837,261)	(2,958,744)	(4,849,787)
Comprehensive Loss	(1,787,745)	(2,974,550)	(4,960,294)
Loss Per Share – basic and diluted	(0.10)	(0.25)	(0.41)
Total Assets	21,376	507,826	2,129,693
Total Liabilities	2,168,689	1,597,254	475,653

During the year ended December 31, 2024, the Company held total assets of \$21,376 (December 31, 2023 – \$507,826), current liabilities of \$2,009,151 (December 31, 2023 – \$1,152,129), and incurred a comprehensive loss of \$1,787,745 (December 31, 2023 – \$2,974,550). The overall decrease in comprehensive loss is due to the Company's cost control efforts.

During the year ended December 31, 2023, the Company held total assets of \$507,826 (December 31, 2022 – \$2,129,693), current liabilities of \$1,152,129 (December 31, 2022 – \$475,653), and incurred a comprehensive loss of \$2,974,550 (December 31, 2022 – \$4,960,294). The overall decrease in comprehensive loss is due to the Company's cost control efforts.

Overall Performance

The following discussion of the Company's financial performance is based on the consolidated financial statements for the year ended December 31, 2024.

The consolidated statements of financial position as of December 31, 2024 indicates a cash balance of \$1,543 (December 31, 2023 - \$55,054), accounts receivable and other receivables of \$17,275 (December 31, 2023 - \$37,161), prepaid expenses of \$2,558 (December 31, 2023 - \$185,834), inventory of \$nil (December 31, 2023 - \$96,305), and total current assets of \$21,376 (December 31, 2023 - \$374,354). The decrease in total current assets was primarily driven by the decrease in prepaid expenses and inventory.

Current liabilities at December 31, 2024 is comprised of account payable and accrued liabilities of \$1,377,764 (December 31, 2023 - \$853,785), due to related parties of \$332,722 (December 31, 2023 - \$146,236), short-term loans of \$8,220 (December 31, 2023-\$152,108), and loan payable of \$290,445 (December 31, 2023 - \$nil). Long term liabilities is comprised of loan payable of \$nil (December 31, 2023-\$238,063) and convertible debentures of \$159,538 (December 31, 2023 - \$207,062). Shareholders' equity is comprised of share capital of \$10,540,839 (December 31, 2023 - \$9,810,979), contributed surplus of \$1,747,090 (December 31, 2023 - \$1,747,090), accumulated other comprehensive loss of \$24,441 (December 31, 2023 - \$73,957) and deficit of \$14,410,801 (December 31, 2023 - \$12,573,540).

Working capital deficit is \$1,987,775 (December 31, 2023 - \$777,775).

During the year ended December 31, 2024, the Company reported a comprehensive loss of \$1,787,745 (2023 - \$2,974,550). The overall decrease comprehensive loss is related to the Company incurred less, advertising expenses, consulting fee, employee and related costs, general and administration expenses, insurance expenses, professional fees, research and development expenses, stock based compensation in current year and travel and related expenses.

Management Discussion and Analysis For the Year Ended December 31, 2024

Results of Operations

Year to date ended December 31, 2024

During the year ended December 31, 2024, the Company reported a net loss of \$1,837,261 (2023 - \$2,958,744) and comprehensive loss of \$1,787,745 (2023 - \$2,974,550). The primary factors contributing to these reduced losses include lower, advertising expenses, consulting fees, employee-related costs, general and administration expenses, insurance expenses, professional fees, research and development expenses, stock-based compensation. travel and related expenses.

During the year ended December 31, 2024, the Company recorded operating expenses of \$1,540,313 (2023 - \$2,843,452). The largest factors contributing to the operating expenditures were consulting fees, employee and related costs, research and development expenses.

- Consulting fees. Consulting fees have decreased to \$346,431 (2023 \$462,874) during the year ended December 31, 2024, as the Company has engaged less consultants for professional services, advisory services, communications, sales, accounting and financing and corporate development.
- Employee and related cost. Employee and related cost decrease to \$416,074 from \$688,915, which consists of the salaries paid to operation, sales, research & development for employees.
- Research and development. Research and development expenses have decreased to \$425,335 compare to expenses of \$544,859 in the same year of 2023, due to the Company incurring less expenditures on research and development of new products and improving existing offerings in its line of products.

During the year ended December 31, 2024, the Company recorded other expenses of \$197,960 (2023 – \$14,739). The largest factors contributing to the other expenses were interest expense.

Current quarter

During the quarter ended December 31, 2024, the Company reported a net loss of \$482,728 (December 31, 2023 -\$742,159). The decreased losses were mainly due to the Company incurred less operation expenses during the year compare with 2023.

During the quarter ended December 31, 2023, the Company recorded operating expenses of \$393,326 (December 31, 2023-\$731,945). The most significant factors contributing to the operating expenses were consulting fees, employee and related costs, professional fees, and research and development. Consulting fees of \$91,472 (December 31, 2023-\$95,110) were mainly for consultants providing professional services, advisory services, communications, and corporate development. Employee and related costs of \$29,071 (December 31, 2023 - \$157,248) were related to the decrease in employees and the salaries paid to employees. Professional fees of \$46,827 (December 31, 2023 - \$79,631) were mainly for the fees paid to third-party consultants for professional services, audit fees, and legal fees. Research and development expenses of \$224,253 (December 31, 2023–\$232,556) are related to the expenditures on research and development of new products and improving existing offerings in its line of products.

Summary of Quarterly Results

	December 31, 2024	September 30, 2024	June 30, 2024	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	(10,658)	(44,196)	89,829	182,956	43,536	56,365	61,487	65,881
Net loss	(482,729)	(583,710)	(479,839)	(290,982)	(742,159)	(520,752)	(903,998)	(791,835)
Loss per share, basic and diluted	(0.02)	(0.03)	(0.06)	(0.02)	(0.06)	(0.19)	(0.03)	(0.01)

Management Discussion and Analysis For the Year Ended December 31, 2024

Liquidity and Capital Resources

During the year ended December 31, 2024, the Company incurred a net loss of \$1,837,261 (2023: \$2,958,744), had an accumulated deficit of \$14,410,801 (December 31, 2023: \$12,573,540) and working capital deficiency of \$1,987,775 (December 31, 2023: \$777,775).

The Company is focused on generating sales revenue and is actively pursuing additional sources of financing to ensure that it can meet its ongoing operating requirements. The Company has maintained reasonable general and administrative expenditures, with advertising and promotion of the developed products dependent on the capital available to cover such expenditures.

Operating Activities

Cash flow used in operating activities was \$827,612 for the year ended December 31, 2024 compared to \$1,838,518 in the year ended December 31, 2023, mainly due to less operating expenses incurred in the year of FY2024.

Financing Activities

Cash flow received for finance activities during the year December 31, 2024 was \$774,137 (2023: 811,337), representing net payments to loans of \$142,209 (2023: loan received of \$418,506); funds received of \$186,486 from related parties (2023: 138,236), funds received of \$nil (2023: 254,595) from convertible debentures and net proceeds from issuance of common shares of \$729,860 (2023:\$nil).

The Company's objective is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business.

The Company has defined its capital as shares capital, reserves and accumulated deficit.

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern, to maintain appropriate cash reserves on hand to support continued operations and shareholder returns, maintain capital structure while keeping capital costs at a minimum, and to invest cash on hand in highly liquid, highly rated financial instruments. The company is not exposed to externally imposed capital restrictions, and the Company's objectives and strategies described above have not changed during the year. These objectives and strategies are reviewed on a continuous basis.

Commitments

None.

Transactions with Related Parties

	December 31, 2024	December 31, 2023
Transaction:	\$	\$
Transactions with Research & Development Director	68,000	96,000
Salary – CEO	96,154	129,808
Salary – COO/CFO	86,538	129,808
Consulting Fees with a Director	-	32,500
Accounting and related service by Secretary	67,685	88,231
Stock-Based Compensation (directors and officers)	-	142,692
	December 31, 2024	December 31, 2023
Balances:	\$	\$
Amounts owing to CEO	121,204	68,890
Amounts owing to COO/CFO	109,246	77,346
Amounts owing to shareholder	102,272	
Total	332,722	146,236

As at December 31, 2024, the Company had an account payable of \$76,003 (2023 - \$40,503) to the research & development director; \$10,000 (2023 - \$51,074) to a director, and \$87,810 (2023 - \$nil) to the secretary.

As at December 31, 2024, the Company had a loan payable \$40,738 (2023 - \$33,364) to the CEO, and \$96,823 (2023 - \$79,384) to the COO/CFO.

As at December 31, 2024, the Company had a short-term loan of \$8,220 (2023 - \$nil) from a shareholder.

These transactions are in the normal course of operations. The stock-based compensation is estimated at fair value, and the others are measured at the exchange amount, which is the amount agreed upon between the related parties.

Critical Accounting Estimates and Changes in Accounting Policies

All significant critical accounting estimates and change in accounting policies are fully disclosed in Note 3 of the consolidated financial statements for the year ended December 31, 2024

Financial Instruments and Financial Risk

IFRS 13 establishes a fair value hierarchy that prioritizes the input to valuation techniques used to measure fair value as follows:

- Level 1 Value based on unadjusted quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 Valuation techniques based on inputs other than quoted prices that are observable for assets or liabilities, either directly (ie. as prices) or indirectly (ie. derived from prices); and
- Level 3 Valuation techniques using inputs for assets or liabilities that are not based on observable market data (unobservable inputs).

As of December 31, 2024 and December 31, 2023, the carrying value of the Company's financial instruments approximate their fair values due to the short-term nature.

Management Discussion and Analysis For the Year Ended December 31, 2024

Financial risk management objectives and policies

The Company's financial instruments consist of cash, accounts receivable and other receivables (excluding tax payables), accounts payable and accrued liabilities, due to related parties, short-term loans, loan payable, and convertible debentures.

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company limits its exposure to credit risk on cash and cash equivalents and trade and other receivables. The Company limits its exposure to credit risk on cash and cash equivalents by depositing only with reputable financial institutions. Credit risk is primarily associated with trade receivables, as the Company grants credit to its customers in the normal course of business. Credit risk on trade receivables is minimized by performing credit reviews, ongoing credit evaluation and account monitoring procedures. All trade receivables were allowed for credit loss at December 31, 2024 due to long aging of the balance and the Company ceased operation in 2024.

Foreign exchange risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The functional currency of the Company is the Canadian dollar and the functional currency of PBF is US dollar. A significant change in the currency exchange rates between the US dollar relative to the Canadian dollar could have an effect on the Company's results of operations, financial position and cash flows. The Company has not entered into any derivative financial instruments to manage exposures to currency fluctuations. The fluctuation in the US dollar against the Canadian dollar would not have material impact on the Company's consolidated statements of operations and comprehensive loss, based on amounts held at year end.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company does not have floating rate debt.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash.

Historically, the Company sole sources of funding were from issuance of subordinate voting shares and multiple voting shares, shareholder loan, short-term loans and revolving debt. The Company's access to financing has at times been uncertain. There can be no assurance of continued access to significant debt or equity funding.

Subsequent Events

Subsequent to December 31, 2024, the Company closed its strategic reorganization pursuant to the terms of a Share Purchase Agreement dated April 2, 2025, with PBF, a private California-based company, and certain insiders of the Company (together, the "Purchasers"). This reorganization was approved by shareholders and regulatory body.

Management Discussion and Analysis For the Year Ended December 31, 2024

As part of the transaction, all outstanding shares of PBF were transferred to the Purchasers in exchange for the surrender of their securities in the Company. This resulted in the cancellation and return to treasury of 800,000 multiple voting shares and 600,000 subordinate voting shares of the Company. In addition to the share transfer, PBF transferred to the Company its proprietary recipes, trademarks, and related intellectual property assets (the "IP") in return for the Company forgiving approximately \$5.5 million in intercompany debt and granting PBF an exclusive license for the use of the IP within the United States, in exchange for a royalty on revenues derived therefrom.

Off Balance Sheet Arrangements

To the best of management's knowledge, there are no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the results of operations or financial condition of the Company.

Proposed Transactions

The Company does not currently have any proposed transactions approved by the Board of Directors. All current transactions are fully disclosed in the consolidated financial statements for the year ended December 31, 2024.

Principal Use of Available Funds

Reconciliation of Use of Proceeds from Major Financing in 2021

During the year 2021, the Company completed Major Financing and received funds of \$6,316,071. The Company filed a final prospectus (the "Prospectus") dated December 17, 2021 on SEDAR. As of November 30, 2021, being the most recent month end before the date of the Prospectus, the Company had working capital of approximately US\$5,752,629.

The following table sets forth the principal purposes for which the estimated use of funds available to the Company would be used per the Prospectus and the actual use of funds:

	Estimated	Actual	
Use of Funds Available	Use of Funds Available	Use of Funds	Variance
Objective A – Develop product line (1)	US\$497,000	US\$570,407	Variance can be explained due to increased in the cost to refine its product line.
Objective B – Expand production and sales operations	US\$1,382,000	US\$1,022,737	Variance can be explained due to the delay in completing all planned sales.
Objective C – Engage in marketing activities ⁽¹⁾	US\$1,434,000	US\$1,181,467	Variance can be explained due to the delay in completing all planned marketing activities.
Listing Costs (2)	US\$50,000	US\$178,298	Increased legal fees for the prospectus translation from English to French and listing in OTC markets.
Operating Expenses for 12 months (3)(4)	US\$1,419,000	US\$1,497,472	Variance can be explained due to increased normal operating expenses.
Finder's fee ⁽⁵⁾	US\$334,727	US\$331,356	The Company paid the finder's fee in the Canadian dollar; the difference is due to the foreign exchange rate fluctuates.
Unallocated Working Capital (6)	US\$937,066	US\$970,892	The working capital available will be used to accomplish the business objectives and milestones that have not been completed.
Total	US\$5,752,629	US\$5,752,629	

Notes:

- (1) See "Business Objectives and Milestones" for breakdown of costs.
- (2) Listing costs are comprised of filing fees, legal fees and auditor fees.
- (3) The estimated operating expenses for the next 12 months (December 1, 2021 to November 30, 2022) in the amount of US\$1,419,000 include costs related to: accounting (US\$36,000); legal (US\$250,000); consulting (US\$125,000); labor (US\$750,000); insurance (US\$45,000); utilities (US\$36,000); office supplies (US\$5,000); travel (US\$72,000); rent (US\$60,000); and shipping (US\$40,000). The amount of US\$750,000 originally budgeted for labor costs consists of: US\$350,000 payable to the Company's management team (including US\$100,000 that is currently unallocated and may be used to pay the Chief Financial Officer, the Chief Innovation Officer or any new executives engaged by the Company); US\$125,000 payable for administrative staff; US\$180,000 payable to sales staff; US\$65,000 payable in payroll tax; and US\$30,000 payable in workers compensation expenses.
- (4) The estimated operating expenses for the next 12 months (December 1, 2021 to November 30, 2022) are based on a no-sales revenue budget.

Management Discussion and Analysis For the Year Ended December 31, 2024

- (5) Represents the cash portion of the finder's fee payable to certain finders in connection with the Major Financing, being C\$423,765.
- (6) Unallocated working capital may be used to repay immaterial indebtedness, labor, marketing, expanding the Company's product line, production and sales operations, general working capital and other uses as may be necessary.

While the Company intends to spend its original working capital as stated above, there may be circumstances where, for sound business reasons, a re-allocation of funds may be necessary or advisable. The actual amount that the Company spends in connection with each of the intended uses of proceeds may vary significantly from the amounts specified above, and will depend on a number of factors, including those listed under the heading "Risk Factors".

Business Objectives and Milestones

The objectives and milestones as outlined in the Prospectus are analyzed as follows:

	Target Completion Date	Target Budget	Current Status
Objective A: Develop product line			
Milestone 1 : Approve final packaging designs for new products.	Q4 2021	US\$225,000	Completed.
Milestone 2 : Prepare and file documentation required to patent and trademark all product stock-keeping units and proprietary processes.	Q3 2022	US\$144,000	Completed.
Milestone 3: Test new ingredients and concepts.	Q3 2022	US\$128,000	Completed.
	Subtotal	US\$497,000	
Objective B: Expand production and sales operations			
Milestone 1: Approve plant designs and installation of various equipment.	Q4 2021	US\$412,000	The Company has partnered with two manufacturing partners.
Milestone 2 : Establish satellite office in Metro-Denver area.	Q3 2022	US\$60,000	The Company supports one employee in the Denver area.
Milestone 3: Establish sales teams across the USA.	Q4 2022	US\$910,000	The Company has 2 Full time, and 2 part time sales executives focused on the West Coast and Rocky Mountain regions.
	Subtotal	US\$1,382,000	

Objective C: Engage in marketing activities

Milestone 1 : Create marketing plans and initiate social media advertising.	Q4 2021	US\$120,000	Completed within the budget
Milestone 2 : Launch website, digital receipt menu, ecommerce platform and digital marketing.	Q4 2021	US\$140,000	Completed within the budget
Milestone 3: Publish articles to further brand validation.	Q4 2021	US\$300,000	Completed within the budget
Milestone 4: Commence seasonal marketing.	Q4 2021	US\$40,000	Completed within the budget
Milestone 5 : Invite social media influencers to test products and introduce products to their networks.	Q4 2021	US\$330,000	Completed within the budget
Milestone 6: Attend trade shows and conventions.	Q4 2021	US\$120,000	Completed within the budget
Milestone 7: Expand social media marketing.	Q4 2022	US\$384,000	Completed within the budget.
	Subtotal	US\$1,434,000	

Total (Objectives A to C) US\$3,313,000

Reconciliation of Use of Proceeds from a Private Placement in August 2023

In August 2023, the Company closed a non-brokered private placement for gross aggregate proceeds of CAD\$341,000. The following table sets out a comparison of how the Company used the proceeds following the closing date, an explanation of the variances and the impact of the variance on the ability of the Company to achieve its business objectives and milestones.

Intended Use of Proceeds	Actual Use of Proceeds
For general working capital and corporate purposes.	During the year ended December 31, 2023, the Company was working with New Leaf Community Markets and Lunardi's Markets. Subsequent to December 31, 2023, New Leaf Community Markets and Lunardi's Markets have authorized the sales of Planet Based Foods Global Inc.'s original-with-cheese and southwest-style taquitos across their respective locations.
Explanation of variances and the impact of variances on the ability of the Company to achieve its business objectives and milestones	No material variances have been identified. Proceeds have been used as intended and to further business development while meeting administrative requirements.

Summary of Outstanding Share Data

a) Share capital

Authorized: Unlimited Subordinated Voting Shares without par value Unlimited Multiple Voting Shares without par value

Management Discussion and Analysis For the Year Ended December 31, 2024

> As at the date of this MD&A, the Company's share capital is as follows: Issued and outstanding 19,747,139 Subordinated Voting Shares Issued and outstanding nil Multiple Voting Shares

b) Warrants

As at the date of this MD&A, the Company has 234,000 warrants issued and outstanding.

c) Stock Options

As at the date of this MD&A, the Company has 550,000 options issued and outstanding.

d) Restricted Share Units

As at the date of this MD&A, the Company has 654,000 RSUs issued and outstanding.

For additional details of outstanding share capital, refer to Notes 14 of the consolidated financial statements for the year ended December 31, 2024.

Other MD&A Requirements

Additional Disclosure for Venture Issuers without Significant Revenue

The following is a breakdown of the material costs incurred:

	December 31, 2024	December 31, 2023
	\$	\$
Purchase Raw Materials and Produced Inventory	316,919	327,821
Research and Development Costs Expensed	425,335	544,859
Advertising and Related	29,572	387,302
Consulting fees	346,431	462,874
Employee and related costs	416,074	688,915
Professional Fees	107,790	134,421
Travel and related	2,836	48,377
Other General Operating Expenses	169,332	545,574
Stock based compensation	-	146,422

Industry and Economic Factors Affecting Performance

The Company is in a development stage in a vegan food processing marketplace that itself has experienced tremendous growth. In addition, as the diverse consumer foods market questions highly processed and genetically modified ingredients, there is an embrace and movement towards sustainable, organic, plant-based foods, while also addressing taste and texture. The demand for hemp derived products, including Cannabidiol ("CBD") and foods developed from the plant has grown exponentially. The Company differentiates itself in this market by hemp being a primary ingredient, where existing competitors source their proteins from corn or soy. These market opportunities for the Company could be impacted by certain risks, including inflationary pressure on raw material ingredient prices, competition from companies already established in the meat-analog market. Hemp grows in diverse climates, which could prove advantageous as other traditional staple crops could be impacted by changing climate, particularly corn and soy.

Management Discussion and Analysis For the Year Ended December 31, 2024

Risk Factors

The activities of the Company are subject to risks including but not limited to: the Company's reliance on key personnel; the Company's reliance on unpatented proprietary technology and expertise; the competitive and regulatory environment in which the Company operates; the Company's exposure to the price of raw materials; the Company's expectations regarding consumer trends; the Company's ability to manage the supply chain, including the limited number of suppliers of raw materials and the exposure to a disruption in the supply of key ingredients; the Company's ability to protect customers and suppliers information; the Company's exposure to food safety and consumer health issues; the ability of the Company to maintain Planet Based Foods brand and the reputation of the same; a disruption to the distribution channels and/or the production facility; the successful expansion of the Company's manufacturing capacity; the Company's ability to develop innovative products; the Company's ability to retain current customers and/or recruit new customers; the Company may become a party to litigation; the Company's reliance on third party's for shipping and payment processing; the speculative nature of investment risk; the Company's history of losses; the Company may require additional financing to fund future operations and expansion plans through equity or debt; the Company has not paid in the past and does not anticipate paying dividends in the near future; global economic risk may impact consumer demand for the Company's products; the Company may not be prohibited from a business opportunity due to a conflict of interest.

Management

The Company is dependent on a relatively small number of key personnel, the loss of any of whom could have an adverse effect on the Company.

Approval

The Board of Directors of the Company has approved the disclosure contained in this MD&A.

Additional Information

Additional information related to the Company can be found on the Company's website planetbasedfoods.com.